Elsevier

Advanced Drug Delivery Reviews

Volume 169, February 2021, Pages 137-151
Advanced Drug Delivery Reviews

Non-viral COVID-19 vaccine delivery systems

https://doi.org/10.1016/j.addr.2020.12.008 Get rights and content

Abstract

The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.

Cited by (0)

1

Authors contributed equally.

View Abstract